Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Reaffirmed by Zacks Investment Research

Share on StockTwits

Xenon Pharmaceuticals (NASDAQ:XENE)‘s stock had its “hold” rating restated by Zacks Investment Research in a research note issued on Saturday, Zacks.com reports.

According to Zacks, “Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada. “

Several other research analysts also recently weighed in on XENE. BidaskClub downgraded Xencor from a “sell” rating to a “strong sell” rating in a research note on Tuesday, June 11th. Stifel Nicolaus dropped their price target on Restoration Hardware from $180.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, March 29th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $15.00.

XENE stock opened at $10.02 on Friday. Xenon Pharmaceuticals has a 1-year low of $5.41 and a 1-year high of $15.92. The company has a quick ratio of 17.57, a current ratio of 17.57 and a debt-to-equity ratio of 0.18. The company has a market cap of $258.25 million, a P/E ratio of -7.53 and a beta of 1.33. The business has a 50 day simple moving average of $9.87.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.06). On average, equities analysts predict that Xenon Pharmaceuticals will post -1.98 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Northern Trust Corp boosted its position in shares of Xenon Pharmaceuticals by 18.9% during the 4th quarter. Northern Trust Corp now owns 12,246 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 1,948 shares during the last quarter. Geode Capital Management LLC bought a new stake in Xenon Pharmaceuticals in the fourth quarter worth $88,000. Two Sigma Advisers LP bought a new stake in Xenon Pharmaceuticals in the fourth quarter worth $228,000. Falcon Point Capital LLC bought a new stake in Xenon Pharmaceuticals in the second quarter worth $252,000. Finally, Deutsche Bank AG lifted its position in Xenon Pharmaceuticals by 39.6% in the fourth quarter. Deutsche Bank AG now owns 73,200 shares of the biopharmaceutical company’s stock worth $461,000 after buying an additional 20,777 shares during the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

Read More: Bollinger Bands

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.